Lee Kyung Min, Gwon Mi-Ri, Lee Hae Won, Seong Sook Jin, Yoon Young-Ran
Department of Clinical Pharmacology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
BK21 Plus KNU Bio-Medical Convergence Program for Creative Talent, Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Transl Clin Pharmacol. 2021 Sep;29(3):160-170. doi: 10.12793/tcp.2021.29.e16. Epub 2021 Sep 24.
β-Lapachone has been reported to have anticancer and various other therapeutic effects, but is limited in clinical applications by its low bioavailability. pH-Dependent isomerization can be suggested as one plausible factor influencing its low bioavailability. Since it is known that β-lapachone is converted to its isomer, α-lapachone in hydrochloric acid (HCl) solution, isomerization in the human body may be driven by HCl in the gastric fluid. The purpose of this study was to evaluate the possibility of isomerization of β-lapachone in the human body. Chemical reactions were conducted using simulated gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF, pH 7.5) at 37°C. β-Lapachone was observed in SGF at 37°C for 1 hour and SIF for 3 hours. In addition, biofluid analysis was performed on plasma samples 1 hour and 4 hours, and on urine sample 12 hours after oral administration of 100 mg MB12066, a synthetic β-lapachone, in healthy adult male. All samples were analyzed using liquid chromatography-tandem mass spectrometry. Only β-lapachone peaks existed in the spectra obtained from SGF and SIF. No isomerization of β-lapachone was observed in the analysis of any of the human samples. In the current study, the possibility of pH-dependent isomerization of β-lapachone in the human body was not confirmed.
据报道,β-拉帕醌具有抗癌和其他多种治疗作用,但其临床应用因生物利用度低而受到限制。pH依赖性异构化可能是影响其低生物利用度的一个合理因素。由于已知β-拉帕醌在盐酸(HCl)溶液中会转化为其异构体α-拉帕醌,因此人体中的异构化可能是由胃液中的HCl驱动的。本研究的目的是评估β-拉帕醌在人体中异构化的可能性。在37°C下使用模拟胃液(SGF,pH 1.2)和模拟肠液(SIF,pH 7.5)进行化学反应。在37°C下将β-拉帕醌在SGF中观察1小时,在SIF中观察3小时。此外,在健康成年男性口服100 mg合成β-拉帕醌MB12066后1小时和4小时对血浆样本以及12小时对尿液样本进行生物流体分析。所有样本均使用液相色谱-串联质谱法进行分析。从SGF和SIF获得的光谱中仅存在β-拉帕醌峰。在对任何人体样本的分析中均未观察到β-拉帕醌的异构化。在本研究中,未证实β-拉帕醌在人体中存在pH依赖性异构化的可能性。